Biote Corp. Reports 9.5% Revenue Decline and $7.4 Million Net Loss in Q2 2026

Biote Corp. reported a decline in financial performance for the second quarter of 2026, with total revenue of $44.2 million, down 9.5% from $48.9 million in the same period last year. The decrease was primarily driven by a $4.9 million drop in revenue from pellet procedures, attributed to lower procedure volumes at established clinics and reduced productivity at newer clinics. The company estimated that a voluntary recall of certain hormone pellets negatively impacted revenue growth by approximately $3.3 million during the quarter. Service revenue also fell to $851,000 from $1.2 million, largely due to a decline in training revenue. In contrast, revenue from Biote-branded dietary supplements increased by $0.6 million, reflecting higher demand through e-commerce platforms.

The company's net loss for the quarter was $7.4 million, compared to a net income of $3.9 million in the prior year. This shift was influenced by a significant increase in selling, general, and administrative expenses, which rose to $32.4 million from $24.2 million, largely due to legal settlements and increased legal expenses. Additionally, Biote recorded a loss on extinguishment of debt of $648,000, following the refinancing of its credit agreement with Truist Bank. The company’s adjusted EBITDA for the quarter was $5.6 million, down from $15.2 million in the same period last year.

In terms of operational metrics, Biote's total assets decreased to $101.7 million as of June 30, 2026, from $107.6 million at the end of 2025. The company’s cash and cash equivalents also fell significantly to $11.2 million from $24.1 million. The decline in cash was attributed to increased operational costs and the impact of the voluntary recall. Biote's employee headcount remained stable, but the company continues to focus on expanding its network of certified practitioners and clinics to drive future growth.

Strategically, Biote has been working on vertical integration to enhance operational efficiency and reduce production costs. The company acquired Asteria Health, a 503B outsourcing facility, in March 2024, which has been integrated into its operations. However, the company continues to rely on third-party suppliers to meet demand. The recent voluntary recall of hormone pellets has prompted Biote to implement measures to improve inventory management and ensure continuity of care for its clinics. Looking ahead, Biote anticipates challenges due to ongoing economic conditions, including inflation and supply chain constraints, but remains focused on expanding its market presence and enhancing its product offerings.